PEDIATRICS Vol. 66 No. 3 September 1980, pp. 445-454
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, J. C. M.
Right arrow Articles by Mamunes, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, J. C. M.
Right arrow Articles by Mamunes, P.

Renal Hypophosphatemic Rickets: Growth Acceleration After Long-Term Treatment with 1,25-Dihydroxyvitamin-D3

James C. M. Chan MD1, Robert D. Lovinger MD1, and Peter Mamunes MD1

1 Nephrology Section and Genetics-Endocrine-Metabolism Section of the Departments of Pediatrics, Human Genetics, and Pathology, Medical College of Virginia, Health Sciences Division of the Virginia Commonwealth University, Richmond

Treatment with 1,25-dihydroxyvitamin-D3 and phosphorus supplementation for as long as 48 months was evaluated in six patients with renal hypophosphatemic rickets. Previous phosphorus supplementation of 1,800 to 4,000 mg/sq m of body surface area per day was continued while 1,25-dihydroxyvitamin-D3 at 17 to 80 ng/kg of body weight per day was given orally in place of vitamin-D2. The serum calcium concentration stayed within the normal range in the majority of patients, while the serum phosphorus concentration rose from 2.5 ± 0.4 to 3.4 ± 1.2 mg/100 ml after one month (P < .01). With rare exceptions, serum alkaline phosphatase and parathyroid hormone concentrations stayed normal throughout the study. Healing of rickets was demonstrated by radiography. In five patients, growth velocity was evaluated for 12 months before and after therapy. Growth accelerations were 123% to 235% of that expected for changes in chronologic age and 114% to 200% expected for changes in bone age after therapy. Orally administered, 1,25-dihydroxyvitamin-D3 increased renal calcium excretion and calcium retention was achieved by virtue of the decreased fecal calcium loss. In contrast, 1,25-dihydroxyvitamin-D3, even at doses up to 4 µg/day (80 ng/kg/day) did not significantly alter renal phosphaturia. The phosphorus retention was therefore achieved as the result of the decreased fecal phosphate excretion. The absence of hypercalcemia even at high doses of 1,25-dihydroxyvitamin-D3 and the enhanced linear growth support the long-term therapeutic value of 1,25-dihydroxyvitamin-D3 in renal hypophosphatemic rickets.

Submitted on March 26, 1980
Accepted on May 27, 1980




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
F. Jehan, C. Gaucher, T. M. Nguyen, O. Walrant-Debray, N. Lahlou, C. Sinding, M. Dechaux, and M. Garabedian
Vitamin D Receptor Genotype in Hypophosphatemic Rickets as a Predictor of Growth and Response to Treatment
J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4672 - 4682.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
R. M. Savio, J. E. Gosnell, S. Posen, T. S. Reeve, and L. W. Delbridge
Parathyroidectomy for Tertiary Hyperparathyroidism Associated With X-linked Dominant Hypophosphatemic Rickets
Arch Surg, February 1, 2004; 139(2): 218 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
S. G. Dubois, A. F. Ruchon, A. Delalandre, G. Boileau, and D. Lajeunesse
Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport
Am J Physiol Cell Physiol, November 1, 2002; 283(5): C1414 - C1421.
[Abstract] [Full Text] [PDF]